



SASKATCHEWAN FORMULARY BULLETIN

Update to the 62nd Edition of the Saskatchewan Formulary

**Effective September 1, 2013 Exception Drug Status approval
is no longer required for the following:**

**omeprazole, 20mg capsule/tablet (Losec & generics)
rabeprazole, 10mg, 20mg tablet (Pariet & generics)**

Please note that Exception Drug Status approval is still required for omeprazole 10mg.

New Exception Drug Status (EDS) Listings Effective September 1, 2013:

Seebri Breezhaler (glycopyrronium bromide) (NVR)
50mcg inhalation powder hard capsules DIN 02394936

For treatment of:

- a) COPD in patients unresponsive to short-acting beta agonists or short-acting anticholinergic bronchodilators, **OR**
- b) Moderate to severe COPD (i.e. Medical Research Council (MRC) dyspnea scale score 3 to 5), in conjunction with spirometry demonstrating moderate to severe airflow obstruction (i.e. FEV1 < 60 % and low FEV1/FVC < 0.7), without a trial of short-acting agents.

New Inherited Metabolic Disease Benefit Listing Effective September 1, 2013:

Kuvan, (sapropterin dihydrochloride) (BPC)
100mg tablet DIN 02350580

Kuvan is listed as an Inherited Metabolic Disease Benefit for the management of phenylketonuria (PKU) for Saskatchewan Health beneficiaries who meet specific criteria.

Please see the Inherited Metabolic Disease Benefit List
<http://formulary.drugplan.health.gov.sk.ca/FormularyAppxIndOther.aspx> for the criteria and contact the Drug Plan if you have any questions.

**Saskatchewan Ministry of Health
Drug Plan and Extended Benefits Branch
2nd Floor, 3475 Albert Street
Regina, Saskatchewan S4S 6X6
(306) 787-3317
1-800-667-7581**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Ministry of Health. Inquiries should be directed to the address or telephone numbers shown at left.